Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4–VCAM-1 adhesion and macrophage inflammatory protein-1α and MIP-1β production
- 5 December 2008
- journal article
- Published by Springer Science and Business Media LLC in Journal of Bone and Mineral Metabolism
- Vol. 27 (1), 16-23
- https://doi.org/10.1007/s00774-008-0012-z
Abstract
Multiple myeloma (MM) cell adhesion to stromal cells via very late antigen (VLA)-4 and vascular cell adhesion molecule (VCAM)-1 interaction causes enhanced secretion of osteoclastogenic activity by MM cells. We have reported that MM cell-derived macrophage inflammatory protein (MIP)-1alpha and MIP-1beta are responsible for most of the osteoclastogenic activity in MM. Thus, adhesion-mediated osteoclastogenesis may be caused by enhanced production of MIP-1 via VLA-4-VCAM-1 interaction. The present study was undertaken to clarify whether MM cell-derived MIP-1 plays a role in VLA-4-VCAM-1 adhesion-mediated osteoclastogenesis. Adhesion of MM cells to VCAM-1 upregulated MIP-1alpha and MIP-1beta production from MM cells and enhanced production of osteoclastogenic activity by MM cells. Blockade of MIP-1alpha and MIP-1beta actions not only abrogated elaboration of osteoclastogenic activity, but also suppressed spontaneous MM cell adhesion to VCAM-1. These results demonstrate that MM cell adhesion to VCAM-1 upregulates MIP-1 production by MM cells to cause enhancement of osteoclastogenesis. In addition, the results suggest that the increased production of MIP-1 further enhances MM cell binding to stromal cells via stimulation of VLA-4-VCAM-1 adhesion, forming a "vicious cycle" between MM cell adhesion to stromal cells and MIP-1 production via VLA-4-VCAM-1 interaction.Keywords
This publication has 43 references indexed in Scilit:
- Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansionBlood, 2004
- Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysisBlood, 2004
- Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanismsLeukemia, 2003
- RANK ligand and osteoprotegerin in myeloma bone diseaseBlood, 2003
- Role of the Bone Marrow Microenvironment in Multiple MyelomaJournal of Bone and Mineral Research, 2002
- Novel therapies targeting the myeloma cell and its bone marrow microenvironmentSeminars in Oncology, 2001
- RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in OsteoclastogenesisBiochemical and Biophysical Research Communications, 1998
- Establishment and Characterization of an Immortal Macrophage-like Cell Line Inducible to Differentiate to OsteoclastsBiochemical and Biophysical Research Communications, 1998
- Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myelomaEuropean Journal of Haematology, 1996
- Inducible cell adhesion molecule 110 (INCAM-110) is an endothelial receptor for lymphocytes. A CD11/CD18-independent adhesion mechanism.The Journal of Experimental Medicine, 1990